Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Neurology · HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Medical Treatments and Investigational Therapies for HAM/TSP

At a Glance

HAM/TSP has no proven cure, so care focuses on symptom relief and, for some people with worsening disease, off-label corticosteroids. Mogamulizumab and pegylated interferon-alpha remain investigational, while HIV antiretroviral medicines do not treat HAM/TSP alone.

Medical treatment for HAM/TSP is a complex area of care because, currently, there is no proven cure for the condition [1]. Instead, doctors focus on “disease-modifying” therapies—treatments intended to slow down the immune system’s attack on your spinal cord—alongside medications to manage your specific symptoms.

The Role of Corticosteroids

Corticosteroids (often just called “steroids”) are frequently considered for patients with progressive HAM/TSP. They work by suppressing the immune system to calm the inflammation causing bystander damage to your nerves [2].

Because HAM/TSP is rare, evidence supporting steroid use is considered “low quality” (mostly based on observing patients over time rather than large, placebo-controlled trials), and treatments are prescribed “off-label” [1]. The approach is highly individualized, but some specialist centers use a two-stage strategy for actively worsening disease:

  1. Induction (The “Pulse”): For some patients, doctors may use a short course of high-dose methylprednisolone given through an IV (e.g., 1 gram daily for three consecutive days). Small studies note this can lead to temporary improvements in pain and mobility [3][1].
  2. Maintenance: To try and keep inflammation low long-term, some doctors prescribe a low-dose oral steroid, such as prednisolone (e.g., 5mg per day) [1].

Crucial Safety Warnings for Steroids:
Long-term or high-dose steroid use carries significant medical risks that require careful monitoring and prevention plans [2]:

  • Infection Risk: Steroids weaken your immune system, making you more vulnerable to severe infections (or worsening latent infections).
  • Bone Density: They can cause bone thinning (osteoporosis). Your doctor may recommend bone scans and supplements to protect your skeleton.
  • Metabolic and Heart Health: They can cause weight gain, high blood sugar (diabetes), and hypertension (high blood pressure).
  • Eye and Mood Effects: Prolonged use increases the risk of cataracts, glaucoma, and significant mood or psychiatric changes.
  • Adrenal Suppression and Tapering: Never stop taking prolonged oral steroids abruptly. Doing so can cause a life-threatening condition called an adrenal crisis. Your doctor must guide a slow “taper.”

Investigational Therapies

Researchers are exploring newer medications that target the HTLV-1 virus or the immune response more specifically. These are not standard care and are typically only available through clinical trials or special programs.

  • Mogamulizumab: This laboratory-made antibody targets the specific white blood cells where the virus lives. While a major trial showed it reduced the proviral load (the amount of virus in the blood) and inflammatory markers in spinal fluid, it did not significantly improve walking speed compared to a placebo [4]. It also frequently causes a severe skin rash [5][4].
  • Pegylated Interferon-Alpha: This drug helps the immune system fight the virus. Early, small studies combining it with other drugs showed improvements in stiffness (spasticity), but it did not significantly help bladder issues [6]. It is not currently recommended as a standard first-line therapy [1].

A Note on Antiretroviral Therapies (ARVs)

Antiretroviral therapies (ARVs)—the types of drugs used to successfully treat HIV—have no established clinical benefit as a disease-modifying treatment for HAM/TSP alone [1][7]. While ARVs stop HIV from replicating, the HTLV-1 virus behaves differently inside your cells, making standard ARVs ineffective at halting HAM/TSP progression [7][8].

Important: If you are prescribed ARVs because you are co-infected with HIV or for another reason, do not stop taking them. Always consult the clinician managing those medications.

Deciding on Treatment

Because many treatments are off-label or investigational, deciding on a medical plan involves a candid conversation with your neurologist about balancing the potential for slowing the disease against the guaranteed risks and side effects of the medications [2].

Common questions in this guide

Is there a cure for HAM/TSP?
There is currently no proven cure for HAM/TSP. Treatment focuses on managing symptoms and, for people with worsening disease, considering therapies that may reduce inflammation or slow progression.
Are steroids used to treat HAM/TSP?
Some specialist centers use corticosteroids off-label for actively worsening HAM/TSP, sometimes starting with a short course of high-dose intravenous methylprednisolone followed by low-dose oral prednisolone. The evidence is limited, so a neurologist must individualize the plan and weigh possible benefits against risks.
What should be monitored if I take steroids for HAM/TSP?
Long-term or high-dose steroids can increase infection risk and cause bone thinning, high blood sugar, high blood pressure, cataracts, glaucoma, and mood changes. Your care team may monitor bone density, blood pressure, and blood sugar, and prolonged oral steroids must be tapered rather than stopped suddenly.
Can investigational drugs improve walking in HAM/TSP?
Mogamulizumab lowered the amount of HTLV-1 genetic material in blood and reduced inflammatory markers in spinal fluid in a major study, but it did not significantly improve walking speed compared with placebo. It frequently caused a severe skin rash, so it is not standard treatment and should be discussed only in an appropriate specialist or research setting.
Do antiretroviral medicines treat HAM/TSP?
Antiretroviral medicines used for HIV have no established benefit as a disease-modifying treatment for HAM/TSP alone because HTLV-1 behaves differently from HIV inside cells. If you take antiretroviral medicines for HIV co-infection or another reason, do not stop them without speaking with the clinician who prescribed them.
Are there clinical trials for HAM/TSP treatments?
Newer treatments, including mogamulizumab and pegylated interferon-alpha, are investigational and may be available through clinical trials or special programs. Ask your neurologist whether a trial fits your health, treatment goals, and willingness to accept uncertain benefits and side effects.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that there is no cure, what are the specific goals of the treatment plan we are considering?
  2. 2.Am I a candidate for corticosteroid therapy, and what are the specific risks given my other health conditions?
  3. 3.If we use long-term steroids, what is our plan for monitoring my bone density, blood pressure, and blood sugar?
  4. 4.Can we review the data on investigational drugs like mogamulizumab? Do you think the potential for a severe rash is worth the possible benefit?
  5. 5.Are there any active clinical trials I should consider instead of using medications off-label?
  6. 6.If we start a new treatment, how long will we wait to see if it’s working before deciding to stop?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    Management of HAM/TSP: Systematic Review and Consensus-based Recommendations 2019.

    Araujo A, Bangham CRM, Casseb J, et al.

    Neurology. Clinical practice 2021; (11(1)):49-56 doi:10.1212/CPJ.0000000000000832.

    PMID: 33968472
  2. 2

    Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy.

    Mashkani B, Jalili Nik M, Rezaee SA, Boostani R

    Expert review of neurotherapeutics 2023; (23(12)):1233-1248 doi:10.1080/14737175.2023.2272639.

    PMID: 37933802
  3. 3

    Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.

    Buell KG, Puri A, Demontis MA, et al.

    PloS one 2016; (11(4)):e0152557 doi:10.1371/journal.pone.0152557.

    PMID: 27077747
  4. 4

    Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.

    Sato T, Nagai M, Watanabe O, et al.

    Journal of neurology 2024; (271(6)):3471-3485 doi:10.1007/s00415-024-12239-x.

    PMID: 38430272
  5. 5

    Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.

    Sato T, Coler-Reilly ALG, Yagishita N, et al.

    The New England journal of medicine 2018; (378(6)):529-538 doi:10.1056/NEJMoa1704827.

    PMID: 29414279
  6. 6

    Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis.

    Boostani R, Vakili R, Hosseiny SS, et al.

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2015; (12(4)):887-95 doi:10.1007/s13311-015-0369-3.

    PMID: 26174324
  7. 7

    HTLV-1-associated myelopathy/tropical spastic paraparesis.

    Bangham CR, Araujo A, Yamano Y, Taylor GP

    Nature reviews. Disease primers 2015; (1()):15012 doi:10.1038/nrdp.2015.12.

    PMID: 27188208
  8. 8

    HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors.

    Tardiota N, Jaberolansar N, Lackenby JA, et al.

    Virology journal 2024; (21(1)):14 doi:10.1186/s12985-024-02288-z.

    PMID: 38200531

This page explains treatment options and investigational therapies for HAM/TSP for educational purposes only and does not replace medical advice. Discuss steroid safety, off-label treatments, and clinical trials with your neurologist, and do not stop prescribed ARVs or long-term steroids without medical guidance.

Get notified when new evidence is published on Tropical spastic paraparesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.